“We’re looking at various options,” Zerhouni told analysts during a conference call today. He declined to comment further.
Sanofi will bring two projects into clinical development for biosimilar insulins in a bid to broaden its diabetes portfolio. The French company is facing competition in the insulin field from rivals including Novo Nordisk A/S and Eli Lilly & Co.
“They are not biosimilars of our own molecules,” Sanofi Chief Executive Officer Chris Viehbacher said during the conference call with reporters. He didn’t elaborate.
Sanofi’s top-selling Lantus insulin last year garnered 4.96 billion euros ($6.6 billion) in sales, the company said today. Results from two late-stage trials for a new formulation of Lantus, also known as insulin glargine, are expected in the second quarter, Sanofi also said.
To contact the reporter on this story: Albertina Torsoli in Paris at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org